Oral retinoid

Isotretinoin (Accutane)

The Accutane label gives isotretinoin's elimination half-life as 21 ± 8.2 hours after a single 80 mg dose with food in 74 healthy adults; the app lists 21 hours.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Isotretinoin (Accutane) after one dose: 50% at ~21 h, 25% at 42 h, 12.5% at 63 h.

Drawn from the half-life in the app's model, ~21 h. The model's figures

Half-life About 21 hours Reported in the sources Accutane label: mean ± SD elimination half-lives of isotretinoin and 4-oxo-isotretinoin of 21 ± 8.2 hours and 24 ± 5.3 hours after a single 80 mg dose with food in 74 healthy adults. Absorica label: 18 hours (isotretinoin) and 38 hours (4-oxo-isotretinoin) after a single 40 mg Absorica dose, and approximately 24 hours and 38 hours after a single 32 mg Absorica LD dose. Madan and colleagues: mean ± SD half-life 25.50 ± 7.074 hours fasted and 23.52 ± 6.595 hours fed for a micronized 32 mg formulation.1,2,4 App's figureIn the half-life and pharmacokinetics table Time to peak About 4 hours Reported in the sources Accutane label mean Tmax 3.2 hours fasted and 5.3 hours fed after 80 mg. Absorica label mean Tmax 2.9 hours fasting and 6.4 hours fed after 40 mg, and median 3.5 hours fasting and 5 hours fed for Absorica LD 32 mg. Madan and colleagues: median 3.5 hours fasted and 5.0 hours fed for the micronized 32 mg formulation.1,2,4 App's figureIn the half-life and pharmacokinetics table Bioavailability 25%the app's note calls it an approximate literature figure for fasting Reported in the sources The Accutane label gives no absolute bioavailability. After 80 mg in 74 healthy adults it reports mean isotretinoin AUC from 0 to infinity of 10,004 ng·hr/mL fed against 3,703 fasted, and peak concentrations of 862 against 301 ng/mL, and says exposure was "more than doubled" with a standardized high-fat meal. The Absorica label reports AUC about 50% higher and Cmax 26% higher with a meal for Absorica 40 mg, and 20% and 6% higher for Absorica LD 32 mg.1,2 App's figureIn the half-life and pharmacokinetics table Route and disposition Oral Reported in the sources Isotretinoin is more than 99.9% bound to plasma proteins, primarily albumin; in vitro studies point to CYP2C8, 2C9, 3A4 and 2B6 as the main metabolizing isoforms; after multiple doses in cystic acne patients, exposure to 4-oxo-isotretinoin at steady state was approximately 3.4 times that of isotretinoin.1 App's figureIn the half-life and pharmacokinetics table

Isotretinoin is 13-cis-retinoic acid, an oral retinoid related to vitamin A, sold in the United States under brand names that include Accutane and Absorica.1,2 The Accutane label lists one use, severe recalcitrant nodular acne, says the drug is reserved for patients "who are unresponsive to conventional therapy, including systemic antibiotics", and says it is indicated only for patients who are not pregnant.1 The Absorica label adds an age and pregnancy qualifier, "non-pregnant patients 12 years of age and older", and gives 1982 as the initial US approval year.2 The Accutane label states that the product "is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration", the iPLEDGE risk evaluation and mitigation strategy (REMS).1 The app grades the evidence for isotretinoin as strong, and files it under supplements with the sub-category retinoid and the oral route.

2

How it works

The Accutane label says isotretinoin "inhibits sebaceous gland function and keratinization" and also states "The exact mechanism of action of isotretinoin is unknown".1 In nodular acne patients, the label links clinical improvement to a fall in sebum secretion that "is temporary and is related to the dose and duration of treatment with Accutane".1 The label says the plasma metabolites "possess retinoid activity that is in some in vitro models more than that of the parent isotretinoin", with clinical significance unknown.1 Kapała and colleagues describe, in the introduction of a 2022 review, "A hypothetical part of its action in acne treatment is binding to the retinoic acid nuclear receptors gamma (RAR-γ)", and further effects on keratin production and on sebocytes.3 Those mechanism statements come from a review of the literature, not from a trial that measured them.3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~21 h
Bioavailability
25%
Typical dose
10–80 mg/day
Route
Oral
Time to peak
~4 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 21 hoursAccutane label: mean ± SD elimination half-lives of isotretinoin and 4-oxo-isotretinoin of 21 ± 8.2 hours and 24 ± 5.3 hours after a single 80 mg dose with food in 74 healthy adults. Absorica label: 18 hours (isotretinoin) and 38 hours (4-oxo-isotretinoin) after a single 40 mg Absorica dose, and approximately 24 hours and 38 hours after a single 32 mg Absorica LD dose. Madan and colleagues: mean ± SD half-life 25.50 ± 7.074 hours fasted and 23.52 ± 6.595 hours fed for a micronized 32 mg formulation.1,2,4
Bioavailability25% (the app's note calls it an approximate literature figure for fasting)The Accutane label gives no absolute bioavailability. After 80 mg in 74 healthy adults it reports mean isotretinoin AUC from 0 to infinity of 10,004 ng·hr/mL fed against 3,703 fasted, and peak concentrations of 862 against 301 ng/mL, and says exposure was "more than doubled" with a standardized high-fat meal. The Absorica label reports AUC about 50% higher and Cmax 26% higher with a meal for Absorica 40 mg, and 20% and 6% higher for Absorica LD 32 mg.1,2
Time to peakAbout 4 hoursAccutane label mean Tmax 3.2 hours fasted and 5.3 hours fed after 80 mg. Absorica label mean Tmax 2.9 hours fasting and 6.4 hours fed after 40 mg, and median 3.5 hours fasting and 5 hours fed for Absorica LD 32 mg. Madan and colleagues: median 3.5 hours fasted and 5.0 hours fed for the micronized 32 mg formulation.1,2,4
Route and dispositionOralIsotretinoin is more than 99.9% bound to plasma proteins, primarily albumin; in vitro studies point to CYP2C8, 2C9, 3A4 and 2B6 as the main metabolizing isoforms; after multiple doses in cystic acne patients, exposure to 4-oxo-isotretinoin at steady state was approximately 3.4 times that of isotretinoin.1

The app models isotretinoin with a one-compartment model, and the labels give a different half-life for other formulations (18 hours for Absorica 40 mg).2 The Accutane label reports no statistically significant pharmacokinetic differences between pediatric patients (12 to 15 years, n=38) and adults (n=19).1

The chart below is an illustration of the app's one-compartment model with the twice-daily division the label describes, not a measured curve.

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: two divided doses a day1.

An illustration from a pharmacokinetic model using a half-life of 21 hours. It is not a measured level or a suggested dose.

Deeper analysis: Madan and colleagues, Acta Dermato-Venereologica, 2020

Madan and colleagues at Sun Pharmaceutical Industries reported two open-label, randomized, crossover studies in healthy adults: a fed bioequivalence and food-effect study (n = 71) and a fasting study (n = 18).4 The fed-state micronized 32 mg and Lidose 40 mg products met the 80 to 125% bioequivalence range, the fasted micronized 32 mg product had "~2 times higher bioavailability" than fasted Lidose 40 mg, and food "had no effect on the rate and a marginal effect on the extent of absorption" of the micronized product.4 The same paper reports that the high-fat meal delayed isotretinoin absorption by 1.5 h, with median Tmax 3.5 h fasted and 5.0 h fed for the micronized 32 mg product.4 These studies tested micronized and Lidose products, not the Accutane product, and the Accutane label separately reports total exposure more than doubled with a standardized high-fat meal.4,1 The studies were funded by Sun Pharmaceutical Industries Ltd, and two authors are employees of Sun Pharmaceutical Industries Ltd and one of Sun Pharmaceutical Industries, Inc.4

4

Human studies

The table lists the systematic reviews and the controlled or cohort studies read, with the label's own pooled clinical-trial figures given in the side effects and bloodwork sections.

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Costa and colleagues, Cochrane Database of Systematic Reviews, 20185Systematic review of randomised trials; 12 of the included trials funded by pharmaceutical companies; all except three had high risk of bias in at least one domain31 RCTs, 3836 participants aged 12 to 55 years with mild to severe acne, twice as many male as femaleOutcomes generally measured at 8 to 32 weeks (mean 19.7 weeks); comparators included oral antibiotics plus topical agents and other isotretinoin dosesAgainst oral antibiotics plus topical agents, inflammatory lesion count RR 1.01 (95% CI 0.96 to 1.06; 3 studies, 400 participants, very low-quality evidence); physician's global evaluation RR 1.15 (95% CI 1.00 to 1.32; 2 studies, 351 participants, low-quality evidence); less serious adverse effects RR 1.67 (95% CI 1.42 to 1.98; 2 studies, 351 participants, low-quality evidence); one serious adverse effect, Stevens-Johnson syndrome, in the isotretinoin group (RR 3.00, 95% CI 0.12 to 72.98)
Vallerand and colleagues, British Journal of Dermatology, 20186Systematic review of randomized trials of isotretinoin against control, summarized descriptively; the record read is a short summary only and gives no funding or conflict statement11 trials, 760 patients randomized, mostly men, mean ages 18 to 47.9 years, generally moderate-to-severe acneControl was placebo (2 studies), oral antibiotics (7) or other (2)Isotretinoin reduced lesion counts "always by a greater amount than control"; adverse events 751 with isotretinoin against 388 with control; 12 patients withdrew for adverse events
Kapała and colleagues, International Journal of Environmental Research and Public Health, 20223Single-arm meta-analysis of adverse events across intervention arms; no placebo comparison; no external funding25 RCTs and five open-label trials, 3274 patients with acne vulgarisDaily doses 0.1 to 1.77 mg/kg/day in two parts; durations 8 weeks to about 8.3 monthsDry lips 1344 of 2309 (58.21%); triglyceride elevation 206 of 2000 (10.30%); ALT elevation 50 of 1692 (2.96%)
Lin and colleagues, Postepy Dermatologii i Alergologii, 20257Systematic review of dosing regimens; no external funding15 randomized controlled trialsHigh-dose, low-dose and intermittent regimensAuthors report low-dose and intermittent regimens with "comparable efficacy" to high-dose and fewer mucocutaneous reactions; they call for research on relapse and long-term safety
Cascio Ingurgio and colleagues, Journal of the European Academy of Dermatology and Venereology, 20268Single-centre, randomized, single-blind trial with blinded outcome assessment; grant listed as RochePatients with moderate-to-severe cystic acne; sample size not given in the record readCumulative isotretinoin dose of 120 or 150 mg/kg; 12 months of follow-up after stoppingComparable improvement in severity and lesion counts; relapse 26.7% (120 mg/kg) against 32.3% (150 mg/kg), p = 0.619
Droitcourt and colleagues, Dermatology, 20259Case-time-control study nested in a French national health insurance cohort, 2010 to 2015262,786 patients aged 10 to 25 years treated with isotretinoin; 2,284 hospitalized acute psychiatric eventsExposure start in a 0 to 2 month risk period against a 2 to 4 month reference periodCase-time-control OR 1.01 (95% CI 0.72 to 1.41)
Chen and colleagues, Journal of Affective Disorders, 202210Nationwide population-based cohort, Taiwan National Health Insurance Research Database, 2000 to 201529,943 participants with acne over a 16-year follow-upSubgroups by daily dose (20 mg or less, above 20 mg) and by duration (6 months or less, longer)Adjusted hazard ratio for psychiatric disorders 1.009 (95% CI 0.422 to 1.696) against patients without isotretinoin

Deeper analysis: Costa and colleagues, Cochrane Database of Systematic Reviews, 2018

Costa and colleagues, at Universidade Federal de São Paulo, searched databases up to July 2017 for randomised trials of oral isotretinoin.5 For different doses, one study of 154 participants with severe acne reported 79%, 80% and 84% decreases in total inflammatory lesion count after 20 weeks at 0.05, 0.1 or 0.2 mg/kg/day, and another of 150 participants with severe acne found 58%, 80% and 90% of participants reached a 95% decrease at 0.1, 0.5 and 1 mg/kg/day.5 Fourteen trials (906 participants) comparing doses or regimens reported no serious adverse events, thirteen trials (858 participants) reported less serious effects such as skin dryness, hair loss and itching but could not be pooled, and "None of the included RCTs reported birth defects".5 The authors conclude "Evidence was low-quality for most assessed outcomes", that they are "unsure" whether isotretinoin improves severity on the lesion-count measure against antibiotics plus topical treatment, and that "Daily treatment may be more effective than treatment for one week each month".5 The review lists salary support from Brazilian institutions, and one author (Bagatin) declares money from Bayer for work on adult female acne.5

Deeper analysis: Kapała and colleagues, 2022 single-arm meta-analysis

Kapała and colleagues, at the University of Warmia and Mazury in Olsztyn, searched PubMed, ClinicalTrials and the Cochrane Library for "isotretinoin acne vulgaris" in English from 1980 to 2021, identified 473 studies and assessed 134 in full text.3 Pooled prevalences included dry skin 1584 of 3228 (49.07%), cheilitis 1049 of 2528 (41.50%), epistaxis 536 of 2250 (23.82%), dry or irritated eyes 603 of 2244 (26.87%), headache 207 of 1967 (10.52%), mood changes 53 of 521 (10.17%) and back pain 294 of 1500 (19.60%).3 The authors write that the events "mainly concern mild mucocutaneous conditions (severe cases are rare)" and that "all adverse events are reversible", while the Accutane label states that "Most adverse reactions reported in clinical trials were reversible when therapy was discontinued; however, some persisted after cessation of therapy".3,1 The review states no conflict of interest and no external funding; its arms mix isotretinoin monotherapy with combinations, and rates are not comparisons with a control group.3 The authors list the lack of a placebo, small populations or numbers of intervention arms in some cases, and the inclusion of English-language trials only as limitations.3

Deeper analysis: Cascio Ingurgio and colleagues, 2026 cumulative-dose trial

The trial randomized patients with moderate-to-severe cystic acne to cumulative isotretinoin doses of 120 or 150 mg/kg, with primary outcomes of change in total lesion count and acne severity grade (1 to 8 scale) from baseline to mid-treatment and end of treatment.8 Secondary outcomes were 12-month relapse and scarring; relapse was 26.7% against 32.3% (p = 0.619) and "Scarring did not worsen over the course of treatment".8 The authors state "Adverse events were mild and comparable" between groups, and that "Persistent acne required longer treatment".8 The stated limitations are "Single-centre design and retrospective trial registration".8 The record lists a grant from Roche and gives no further detail on the funder's role or author ties; the sample size, and per-group adverse event counts, are not in the record read.8

Deeper analysis: Droitcourt and Chen, psychiatric outcome cohorts

Droitcourt and colleagues (Rennes University Hospital and Inserm, France), in Dermatology in 2025, compared the timing of isotretinoin starts in people with a hospitalized acute psychiatric event: 88 started in the 0 to 2 months before the event and 81 in the 2 to 4 months before, giving an OR of 1.01 (95% CI 0.72 to 1.41) after comparison with time-trend matched controls (383 and 355).9 The authors write that "Psychiatric events managed outside the hospital system were not recorded", and describe their findings as "reassuring for clinicians concerning the risk of severe acute-onset psychiatric events after isotretinoin initiation".9 The record read gives no funding or conflict statement for this study.9 Chen and colleagues (Tri-Service General Hospital, Taipei), in the Journal of Affective Disorders in 2022, followed 29,943 participants and reported an adjusted hazard ratio of 1.009 (95% CI 0.422 to 1.696), with 0.892 (0.371 to 1.501) at 20 mg a day or less and 1.068 (0.446 to 1.798) above 20 mg a day.10 The authors' stated limitation is "We did not analyze the risk of suicidal ideation, and it could be underestimated in medical claims databases"; the record's publication type is "Research Support, Non-U.S. Gov't" and it gives no author ties to a manufacturer.10

5

Doses reported in studies and on labels

The label dose is weight-based, and the app's range of 10 to 80 mg a day starts below the lowest total in the label's weight table (20 mg a day) and ends below its highest (200 mg a day). The Accutane label's body-weight table lists totals of 20, 40 and 80 mg a day at 0.5, 1 and 2 mg/kg for a 40 kg patient, and 50, 100 and 200 mg a day for a 100 kg patient.1

Table 5.1Doses reported in studies and on labels4 rows
SourceProduct or populationDoseDuration and designReference
Accutane labelSevere recalcitrant nodular acne, taken with food0.5 to 1 mg/kg/day in two divided doses; adult patients whose disease is very severe with scarring or is primarily manifested on the trunk may require adjustments up to 2 mg/kg/day, as tolerated15 to 20 weeks; once daily dosing not establishedAccutane label1
Absorica labelSevere recalcitrant nodular acne, non-pregnant patients 12 years and olderAbsorica 0.5 to 1 mg/kg/day, Absorica LD 0.4 to 0.8 mg/kg/day, in two divided doses with or without meals; adult patients with very severe disease (scarring, trunk involvement) may increase to 2 and 1.6 mg/kg/day15 to 20 weeks; the 20 mg strengths of the two products are not substitutableAbsorica label2
Claravis labelSevere recalcitrant nodular acne0.5 to 1 mg/kg/day in two divided doses with food15 to 20 weeksClaravis label11
Dose-comparison trials in the Cochrane reviewSevere acne, 154 and 150 participants in two trials0.05, 0.1, 0.2 mg/kg/day; 0.1, 0.5, 1 mg/kg/day20 weeks; lesion count decreases of 79%, 80%, 84%; 95% decrease in 58%, 80%, 90% of participantsCosta 20185

The Accutane label notes that all tested doses "provided initial clearing of disease, but there was a greater need for retreatment with the lower dosages", and that "Long-term use of Accutane, even in low doses, has not been studied".1

6

Side effects reported

The Accutane label states that many reactions "are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, e.g., of the lips, nasal passage, and eyes)", that cheilitis and hypertriglyceridemia are usually dose related, and that "Most adverse reactions reported in clinical trials were reversible when therapy was discontinued; however, some persisted after cessation of therapy".1 The boxed warning states "an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking Accutane in any amount, even for short periods of time", and lists abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands.1 The label's psychiatric warning lists depression, psychosis, and rarely suicidal ideation, suicide attempts, suicide and aggressive or violent behaviors, and says "No mechanism of action has been established for these events".1 Other label warnings include pseudotumor cerebri (benign intracranial hypertension), pancreatitis, inflammatory bowel disease, erythema multiforme and severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, and skeletal effects.1 The label's interaction statements are that patients are "advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", and that tetracyclines have been involved in some pseudotumor cerebri cases.1 In the Vallerand review, reasons for withdrawal from the trials included Stevens-Johnson syndrome, cheilitis, xerosis, acne flare, photophobia, elevated liver enzymes, decreased appetite, headaches and depressed mood.6

7

Bloodwork and markers

The Accutane label reports triglyceride elevations above 800 mg/dL, with marked elevations in "approximately 25% of patients receiving Accutane in clinical trials".1 It also reports "approximately 15% developed a decrease in high-density lipoproteins and about 7% showed an increase in cholesterol levels", reversible on stopping in clinical trials.1 Acute pancreatitis has been reported "in patients with either elevated or normal serum triglyceride levels", and the label says the cardiovascular consequences of the hypertriglyceridemia "are unknown".1 The label describes lipid determinations before and during treatment "until the lipid response to Accutane is established, which usually occurs within 4 weeks".1 For liver enzymes the label reports "mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials, some of which normalized with dosage reduction or continued administration of the drug", and says clinical hepatitis considered possibly or probably related has been reported.1 The 2022 meta-analysis gives pooled rates of 4.36% for AST and 2.96% for ALT elevation across its intervention arms.3 The app lists lipids and liver enzymes (ALT, AST) as the markers to monitor, and a hepatotoxic interaction flag.

8

Regulatory and anti-doping status

In the United States the Accutane label places the product under the iPLEDGE REMS, with prescribers, pharmacies and patients enrolled, and monthly pregnancy tests for patients who can become pregnant.1 The label states that such patients must understand responsibility "to avoid pregnancy one month before, during and one month after isotretinoin therapy".1 The label states patients are to be "informed not to donate blood during therapy and for one month following discontinuation of the drug".1 The Absorica label lists an initial US approval year of 1982 and an indication for patients 12 years of age and older.2 Isotretinoin, retinoic acid and retinoids are not named in the text of the WADA 2026 Prohibited List that was read.12 No European Medicines Agency or Therapeutic Goods Administration document for isotretinoin was read.

9

Storage and handling

The Accutane and Absorica labels both state "Store at 20° to 25°C (68° to 77°F)" and "Protect from light".1,2

The Accutane label states that the exact mechanism of action is unknown, and that the mechanism behind the psychiatric events is not established.1 The label states that the optimal interval before retreatment "has not been defined for patients who have not completed skeletal growth" and that the effect of long-term use on bone loss is unknown.1 The Cochrane review says it is "uncertain of the risk of serious adverse effects" and that long-term and low-dose questions remain, and the 2025 dosing review asks for research on relapse and long-term safety.5,7 Neither label read gives an absolute bioavailability, so the app's 25% rests on its own literature note and not on a label figure.1,2

What is the half-life of isotretinoin?

The Accutane label gives a mean elimination half-life of 21 ± 8.2 hours for isotretinoin after a single 80 mg dose with food in 74 healthy adults, and the app lists 21 hours.1 The Absorica label gives 18 hours for isotretinoin after a single 40 mg Absorica dose.2

How long does isotretinoin take to reach its peak level?

The Accutane label gives a mean time to peak of 3.2 hours fasted and 5.3 hours fed after a single 80 mg dose, and the app lists about 4 hours.1 The Absorica label gives 2.9 hours fasting and 6.4 hours fed for a single 40 mg dose.2

What is the bioavailability of isotretinoin?

The app lists 25%, which its own note calls an approximate literature figure for fasting, and neither the Accutane nor the Absorica label gives an absolute bioavailability.1,2 The Accutane label reports that peak concentration and total exposure were "more than doubled" after a high-fat meal compared with fasting in 74 healthy adults.1

Is isotretinoin banned by WADA?

Isotretinoin is not named in the text of the WADA 2026 Prohibited List that was read.12

What is isotretinoin (Accutane) used for?

The Accutane label lists severe recalcitrant nodular acne, reserves the drug for patients unresponsive to conventional therapy, including systemic antibiotics, and says it is indicated only for patients who are not pregnant.1 The Absorica label states the indication for non-pregnant patients 12 years of age and older.2

Does isotretinoin cause birth defects?

The Accutane boxed warning states an extremely high risk of life-threatening birth defects if pregnancy occurs while taking Accutane, in any amount and even for short periods.1 The Cochrane review states that none of the 31 included randomized trials reported birth defects.5 The same review adds that oral isotretinoin is contraindicated during pregnancy due to known teratogenic effects.5

Does isotretinoin raise triglycerides and cholesterol?

The Accutane label reports marked triglyceride elevations in approximately 25% of patients receiving Accutane in clinical trials, a decrease in HDL in approximately 15% and a cholesterol increase in about 7%.1 The 2022 meta-analysis gives 10.30% for triglyceride elevation across 2000 patients in 39 intervention arms.3

Is isotretinoin linked to depression?

The Accutane label states that the drug "may cause depression, psychosis" and, rarely, suicidal behavior, with no mechanism established.1 A French cohort of 262,786 patients reported an OR of 1.01 (95% CI 0.72 to 1.41) for hospitalized acute psychiatric events in the 2 months after starting, and a Taiwanese cohort of 29,943 participants reported an adjusted hazard ratio of 1.009 (95% CI 0.422 to 1.696).9,10 The French authors note that psychiatric events managed outside the hospital system were not recorded, and the Taiwanese authors state that suicidal ideation was not analyzed and could be underestimated in medical claims databases.9,10

What are the most common side effects of isotretinoin?

The 2022 single-arm meta-analysis reports dry lips in 58.21% (1344 of 2309), dry skin in 49.07% (1584 of 3228), flare of acne in 47.92% (46 of 96) and cheilitis in 41.50% (1049 of 2528) across intervention arms.3

13

References

  1. JG Pharma. Accutane (isotretinoin capsules USP). US prescribing information, DailyMed record version 3 (label issued 09/2022). Accutane label
  2. Sun Pharmaceutical Industries. Absorica and Absorica LD (isotretinoin) capsules. US prescribing information, DailyMed record version 21. Absorica label
  3. Kapała J, Lewandowska J, Placek W, Owczarczyk-Saczonek A. Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis. Int J Environ Res Public Health 2022. PMID 35682048
  4. Madan S, Kumar S, Segal J. Comparative Pharmacokinetic Profiles of a Novel Low-dose Micronized-isotretinoin 32 mg Formulation and Lidose-isotretinoin 40 mg in Fed and Fasted Conditions: Two Open-label, Randomized, Crossover Studies in Healthy Adult Participants. Acta Derm Venereol 2020. PMID 31774544
  5. Costa CS, Bagatin E, Martimbianco ALC, da Silva EM, Lúcio MM, Magin P, Riera R. Oral isotretinoin for acne. Cochrane Database Syst Rev 2018. PMID 30484286
  6. Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, Patten SB. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol 2018. PMID 28542914
  7. Lin L, Lin W, Zheng Y, Cai H. Effectiveness and safety of different dosing regimens of isotretinoin for acne vulgaris: a systematic review. Postepy Dermatol Alergol 2025. PMID 41001139
  8. Cascio Ingurgio R, et al. Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial. J Eur Acad Dermatol Venereol 2026. PMID 42223172
  9. Droitcourt C, Kerbrat S, Raby M, Laurent C, Travers D, Balusson F, Oger E, Dupuy A. The Risk of Hospital Admission for an Acute-Onset Psychiatric Disorder in Adolescents and Adults Treated with Isotretinoin: A French, Nationwide, Population-Based, Case-Time-Control Study. Dermatology 2025. PMID 39709951
  10. Chen YH, Wang WM, Chung CH, Tsao CH, Chien WC, Hung CT. Risk of psychiatric disorders in patients taking isotretinoin: A nationwide, population-based, cohort study in Taiwan. J Affect Disord 2022. PMID 34628248
  11. Teva Pharmaceuticals USA. Claravis (isotretinoin) capsules. US prescribing information, DailyMed record version 19. Claravis label
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list